Vincent Cheung is currently the CEO of Nan Fung Group - an international business conglomerate with global interests in real estates, life sciences and financial investments. Vincent is also Chairman of Nan Fung Life Sciences (NFLS), a global investment platform focusing on life sciences, and he co-founded the biotech VC fund Pivotal bioVenture Partners with investment teams in both US and China. Under his leadership, NFLS has built significant presence across the industry (including therapeutics, medical devices and diagnostics) and all development stages.  His vision is to build NFLS to become the ideal partner for scientists, entrepreneurs, corporations and investors in the life sciences space.

Vincent has been a member of The National Committee of the Chinese People’s Political Consultation Conference for Shanghai City since 2012, a Committee Member of the All-China Youth Federation since 2010, a Committee Member of All-China Financial Youth Federation and a Member of Shanghai Youth Federation.

Vincent graduated with high honours in Molecular and Cell Biology from University of California, Berkeley. While in Berkeley, he worked in Lawrence Berkeley National Laboratory as an independent researcher.

Gerald Chan is the co-founder of Morningside, a private investment group with venture capital, private equity and property investments.

Combining his training in science and experience in investments, Gerald has led the start-up of many biotechnology companies. His investments enabled many pioneering technologies in oncology including oncolytic viruses (Biovex, DNATrix), immuno-oncology (Aduro), novel cytotoxic agents (Nucana), modified tumor microenvironment (Vigeo) and novel targets for therapeutic intervention (CellCentric, K-Gen). Investments in the infectious disease area include novel antibiotics (MicuRx, Artugen), prophylactic vaccines (Matrivax) and antiviral small molecule drugs (Atea). Other investments cover the therapeutic areas of metabolic diseases (CVI, Alms), autoimmune diseases (Kezar), CNS disorders (Orthogonal, Pinteon, Cognito, Cognoa, Amylyx), and rare orphan diseases (Stealth, Apellis).

Gerald is a member of Harvard University’s Global Advisory Council, the Dean's Board of Advisors of the Harvard T.H. Chan School of Public Health and the Harvard China Fund. He chairs the Overseers Committee of the Morningside College of Chinese University of Hong Kong and the Innovation Advisory Committee of the Wellcome Trust in London.

Gerald received his BS and MS degrees in engineering from UCLA, his Master's degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He did his post-doctoral training at the Dana-Farber Cancer Institute. The Chinese University of Hong Kong, University of Glasgow, Hong Kong University of Science and Technology, Scripps Research Institute and University of Massachusetts Boston have conferred on him honorary degrees. He was elected to an honorary fellowship at Wolfson College of Oxford University.

Shannon Cheung joined Pivotal China in 2018. He is also the Founder and Chief Executive Officer of Averest Capital, an investment company focusing on healthcare and TMT sectors, and Co-Founder and Vice Chairman of Likang Life Sciences. Shannon has participated in the investment of over 40 technology companies in China, including Alibaba Group, Hero Entertainment, VSPN, China Music Corporation (currently known as Tencent Music), CMGE, Yixin Group, Alltech Medical Systems, MChang, All Football, 91huayi.com (China’s largest online continuing education platform for doctors). Prior to Averest Capital, Shannon was Managing Director of global banking coverage in HSBC Markets (Asia) Limited and Chief Representative of HSBC (Securities Business) Beijing Representative Office, where he was responsible for business origination of investment banking in China, including IPOs and other equity related products, M&A advisory and high yield bond issuance.

Shannon is the Founder and President of Fin Society, a non-profit professional fraternity aiming to enhance the competitiveness of finance practitioners in Hong Kong and nurture next-generation finance industry leaders. He is also a recipient of the Medal of Honour from the Government of Hong Kong.

Shannon holds a Bachelor of Commerce degree with distinction from the University of Calgary.

Nancy Y. Ip is currently the President, The Morningside Professor of Life Science, and the Director of the State Key Laboratory of Molecular Neuroscience at The Hong Kong University of Science and Technology. She received her PhD degree in Pharmacology from Harvard University, after which she held the position of Senior Staff Scientist at Regeneron Pharmaceuticals Inc. in New York. Since joining HKUST in 1993, she has served as the Vice-President for Research and Development, Dean of Science, Director of the Biotechnology Research Institute, and Head of the Department of Biochemistry.

Professor Ip is world-renowned for her significant contributions to the field of neuroscience. Her outstanding research has resulted in 328 scientific papers and 70 patents. The excellence of her work has been recognized through numerous prestigious awards and honors including the L’OREAL-UNESCO for Women in Science Award, the National Natural Science Awards, 10 Science Stars of China by Nature, and Chevalier de l’Ordre National du Mérite (National Order of Merit) by the French Government. As a further testament to her distinguished achievements, Ip has been elected to the Chinese Academy of Sciences, the US National Academy of Sciences, the World Academy of Sciences, the American Academy of Arts and Sciences, the Hong Kong Academy of Sciences, and the Chinese Academy of Medical Sciences.

Antony Leung, former Financial Secretary of Hong Kong Special Administrative Region, is Group Chairman of Nan Fung Group, a leading regional conglomerate focusing on property & investment businesses.  He is also Group Chairman & Co-Founder of New Frontier Group, a group that engages in health care, elderly services and investment business in China. Concurrently, Antony is Independent Non-Executive Director of China Merchants Bank, Chairman of two charity organizations - Heifer Hong Kong and Food Angel.

Antony also has extensive experience in financial services, including Chairman of Greater China of Blackstone, Chairman of Asia of JP Morgan Chase, Asia Head of Citi Private Bank, Regional Head of Citi Investment Bank, Treasury and Greater China.  In addition, he was Independent Director of Industrial and Commercial Bank of China, China Mobile (Hong Kong) Limited, American International Assurance (Hong Kong) Limited, International Advisory Board Member of China Development Bank and Chairman of Harvard Business School Association of Hong Kong. His past public service included Non-Official Member of the Executive Council, Chairman of Education Commission, Chairman of University Grants Committee, Member of Exchange Fund Advisory Committee, Director of Hong Kong Airport Authority and Hong Kong Futures Exchange, Member of the Preparatory Committee and Election Committee for the Hong Kong Special Administrative Region and Hong Kong Affairs Advisors.

Dennis Lo is the Director of the Li Ka Shing Institute of Health Sciences, the Chairman of Department of Chemical Pathology, the Li Ka Shing Professor of Medicine and Professor of Chemical Pathology of The Chinese University of Hong Kong (CUHK). He is also the Associate Dean (Research) of the Faculty of Medicine of CUHK. Prof Lo received his Bachelor of Arts degree from the University of Cambridge and the Doctor of Medicine and Doctor of Philosophy degrees from the University of Oxford.

Prof Lo discovered the presence of cell-free fetal DNA in maternal plasma in 1997, and has since then remained at the forefront of the field of non-invasive prenatal testing (NIPT). NIPT is now available in over 90 countries, benefiting millions of pregnant women every year. Prof Lo sees the parallels between circulating fetal DNA and circulating tumour DNA and has made pioneering contributions to the liquid biopsies for cancer, especially for the early detection and monitoring of nasopharyngeal carcinoma.

In recognition of his work, Prof Lo has been the recipient of numerous awards, including the King Faisal International Prize in Medicine in 2014 and the Future Science Prize – Life Science Prize in 2016. He was elected as a Fellow of the Royal Society in 2011, as a Foreign Associate of the US National Academy of Sciences in 2013 and as a Founding Member of the Academy of Sciences of Hong Kong in 2015.